Outcomes of a 2nd comparative review were described by Flinn et al. This is a phase III randomized Intergroup trial evaluating FC program vs . FAMP alone in 278 sufferers acquiring their initial chemotherapy regimen for B-CLL. Dosages of FC agenda had been similar to the first examine. Title your https://patrickn776zka2.blogars.com/profile